1. NPSA Rapid Response Report: Safer administration of insulin, NPSA/2010/RR013; 2010. Available from: https://www.sps.nhs.uk/wp-content/uploads/2018/02/2010-NRLS-1243-Safer-administrnsulin-2010.06.16-v1.pdf [Accessed 04 Mar 2021].
2. ICS UK. Medication concentration in critical care areas; 2017. Available from: https://ics152.files.wordpress.com/2017/02/ics-standard-medication-concentrations-2016.pdf [Accessed 04 Mar 2021].
3. Insuman® Rapid 100 I.U./mL. Summary of product characteristics, Updated July-2020. Frankfurt, Germany: Sanofi-Aventis Deutschland GmbH. Available from: https://www.fachinfo.de/api/fachinfo/pdf/022037 [Accessed 04 Mar 2021].
4. Crommelin, DJA, Sindelar, RD, Meibohm, B. Pharmaceutical biotechnology: fundamentals and applications, 3rd ed. Informa Healthcare USA Inc; 2008:265–80 pp.
5. Ohno, Y, Seki, T, Kojima, Y, Miki, R, Egawa, Y, Hosoya, O, et al.. Investigation of factors that cause insulin precipitations and/or amyloid formation in insulin formulations. J Pharm Health Care Sci 2019;5:22. https://doi.org/10.1186/s40780-019-0151-5.